Natco Pharma shares drop 2% after FDA notes procedural observation at Hyderabad facility, down 36% year to date.

• U.S. FDA inspection of Hyderabad plant raises concerns with one procedural observation.
• The company is confident in addressing FDA issues comprehensively, but no details have been disclosed.
• Stock averages 'hold' rating, median price target at 935.50 rupees.